Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx

Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx

In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2−) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET) in a subgroup of patients under 50 years with an intermediate Oncotype DX recurrence sc...

Full description

Bibliographic Details
Main Authors: Elena Diana Chiru, Anton Oseledchyk, Andreas Schoetzau, Christian Kurzeder, Raphael Mosimann, Marcus Vetter, Cvetka Grašič Kuhar
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Diagnostics
Subjects:
oncotype
recurrence score
breast cancer
genomic risk
chemotherapy
genomic assay
Online Access:https://www.mdpi.com/2075-4418/14/1/97

Internet

https://www.mdpi.com/2075-4418/14/1/97

Similar Items